← Back to Search

A2 Donor Lungs for O Recipient Transplant

N/A

Recruiting

Led By Shaf Keshavjee, MD MSc FRCSC FACS

Research Sponsored by University Health Network, Toronto

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 10 years

Awards & highlights

Study Summary

This trial will study the safety of A2-O kidney and liver transplants, and the feasibility of A2-O lung transplants, to increase organ donation and reduce wait times for O patients.

Who is the study for?

This trial is for individuals who need their first lung transplant, have blood group O, and low levels of anti-A antibodies before surgery. They must consent to participate in the study. People needing a re-transplant or multiple organ transplants, or those with positive virtual crossmatch at the time of transplant cannot join.Check my eligibility

What is being tested?

The study is testing if lung transplants from donors with blood group A2 to recipients with blood group O are safe and can help reduce waiting times for these patients. It's the first worldwide prospective study on this type of ABO-incompatible lung transplant.See study design

What are the potential side effects?

Potential side effects may include immune reactions due to blood type incompatibility, increased risk of infection post-surgery, and complications related to standard lung transplant procedures.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 10 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~10 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 10 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Hemorrhage

C4d positivity on transbronchial biopsy samples

Lung

+8 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: A2 donor transplant to O recipientExperimental Treatment1 Intervention

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor

1,475 Previous Clinical Trials

485,080 Total Patients Enrolled

2 Trials studying Lung Transplant

320 Patients Enrolled for Lung Transplant

Shaf Keshavjee, MD MSc FRCSC FACSPrincipal InvestigatorUniversity Health Network, Toronto

1 Previous Clinical Trials

200 Total Patients Enrolled

Media Library

Blood group A2 donor to blood group O recipient lung transplant surgery Clinical Trial Eligibility Overview. Trial Name: NCT05581745 — N/A

Lung Transplant Research Study Groups: A2 donor transplant to O recipient

Lung Transplant Clinical Trial 2023: Blood group A2 donor to blood group O recipient lung transplant surgery Highlights & Side Effects. Trial Name: NCT05581745 — N/A

Blood group A2 donor to blood group O recipient lung transplant surgery 2023 Treatment Timeline for Medical Study. Trial Name: NCT05581745 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still opportunities to apply for this clinical experiment?

"Affirmative. Clinicaltrials.gov conveys that the trial is actively searching for participants, which was initially posted on July 14th 2022 and updated most recently on October 20th 2022. This experiment requires 10 human test subjects to be recruited from 1 particular site."

Answered by AI

How many participants are contributing to this clinical research?

"Affirmative. Evidence on clinicaltrials.gov suggests that this medical research, initially posted on July 14th 2022, is currently enrolling candidates. A total of 10 patients must be recruited from 1 healthcare facility."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A2 to O Lung Transplants

2022. "A2 to O Lung Transplants". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05581745.